To this end, we here preliminarily compared the safety and efficacy index of anti‐CLL1‐based CAR T‐cells between those equipped with 4‐1‐BB domain and CD27/CD28 domain in treating children with R/R‐AML. This evidence concerns the gene CD27 and acute myeloid leukemia.